お知らせ • Oct 01
Syntara Limited, Annual General Meeting, Nov 20, 2025 Syntara Limited, Annual General Meeting, Nov 20, 2025. お知らせ • Sep 30
Syntara Limited, Annual General Meeting, Nov 28, 2024 Syntara Limited, Annual General Meeting, Nov 28, 2024. お知らせ • Aug 16
Syntara Limited Announces CFO Changes Syntara Limited announced the appointment of Tim Luscombe as Chief Financial Officer (CFO) for Syntara, effective 31 August 2024. Tim replaces Mr. David McGarvey, who is retiring after more than 20 years as the CFO of Syntara, and before that Pharmaxis. David will continue in his role as Company Secretary to the Board. Tim is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. Tim has more than 10 years of finance and commercial experience working with public and private companies in Australia and abroad. He currently serves as a CFO and Company Secretary for several ASX-listed, public unlisted and private companies. Tim holds a Bachelor of Commerce from the University of Melbourne, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. In addition to his role as Company Secretary Mr. McGarvey will give special attention to concluding financial and legal arrangements associated with the sale of the mannitol business unit. お知らせ • Apr 24
Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024 Syntara Limited announced that they will report Q3, 2024 results on Apr 30, 2024 お知らせ • Feb 06
Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million. Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 108,392,130
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00022
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 346,153,325
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00022
Transaction Features: Subsequent Direct Listing お知らせ • Dec 20
Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million. Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 108,400,000
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00022
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 346,200,000
Price\Range: AUD 0.022
Discount Per Security: AUD 0.00022
Transaction Features: Subsequent Direct Listing お知らせ • Oct 20
Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis. Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023. Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis on October 19, 2023. お知らせ • Oct 05
Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis. Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis on October 3, 2023. the sale is scheduled to complete before the end of October 2023. お知らせ • Sep 13
Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023 Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023, at 11:01 AUS Eastern Standard Time. お知らせ • Jan 17
Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director Pharmaxis Ltd. announced the appointment of healthcare investment professional Hashan De Silva to the Board as a nonexecutive director. Mr. De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr. De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals. Mr. De Silva was educated at the University of New South Wales (Bachelor's Degree in Medicine and Master's Degree in Finance) and is a Chartered Financial Analyst. Until December 2022 Mr. De Silva was Head of Healthcare Research at Karst Peak Capital Limited, a Hong Kong and Australian based specialist healthcare fund and is a nonexecutive director of Melbourne and Philadelphia based CurveBeam AI. Mr. De Silva is based in Sydney Australia and commences his role as nonexecutive director on 16 January 2023. お知らせ • Dec 22
Pharmaxis Announces Clinical Trial of Its Topical Anti Scarring Drug PXS6302 Complete Recruitment with the Last of the 42 Patients Pharmaxis announced that the clinical trial of its topical anti scarring drug PXS6302 has completed recruitment with the last of the 42 patients dosed earlier this week. The study is being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM, Director of the Western Australia Burns Service. The trial, known as SOLARIA2, is in 50 adult patients treated for scars of greater than one year in age and over 10cm2 in size for a period of 3 months. The first 8 patients treated were on active drug whereas the following 42 were randomised 1:1 to active or placebo. Preliminary results, released in September from the open label phase with 8 patients treated for up to 3 months on active drug, showed a high level of inhibition of enzymes and changes in biomarkers that are implicated in scarring with Professor Fiona Wood commenting. Final results are scheduled for second quarter 2023 when the company hopes to confirm an acceptable safety profile, improvements in scar appearance and function for patients on active drug relative to those treated with placebo, and evidence that LOX inhibition is modifying scar tissue at a structural and biochemical level. PXS6302 was discovered by the company research team at the company's Frenchs Forest laboratories. The project was supported by a National Health and Medical Research Council (NHMRC) development grant which funded extensive preclinical work executed in collaboration with UWA. The ongoing clinical trial in patients with established scars and the planned follow up study will both be conducted at the Fiona Stanley Hospital in Perth with financial support from the company. お知らせ • Dec 14
Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive Director Pharmaxis Ltd. announced the appointment of experienced senior global pharma executive Dr Simon Green to the Board as an independent nonexecutive director. Dr Green has 30 years of experience in the biotechnology industry focused on the discovery, development and commercialization of life saving medicines. He worked in the USA at leading biotechnology companies Genentech Inc. and Chiron Corporation prior to joining CSL in 1998. Dr Green was actively involved in CSL's global expansion over a 17 year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Dr Green's breadth of skills covers R&D drug development, corporate due diligence, mergers and acquisitions, strategic planning, portfolio management, financial management, intellectual property management, business development, contract management and organizational design. Dr Green was educated at Monash University (Bachelor's Degree with Honours) and the University of Melbourne (Doctor of Philosophy, Biochemistry and Immunology). He is a graduate of the Australian Institute of Company Directors Company Directors Course. Dr Green is a nonexecutive director of Clover Corporation Limited and is the founder and CEO of Immunosis Pty Ltd, a startup diagnostics Company. He is also a Venture Partner and investment advisor at BioScience Managers, a healthcare investment firm and serves on the scientific advisory board for Imunexus Pty Ltd. Dr Green is based in Melbourne Australia and will take up his role as nonexecutive director on 16 December 2022. お知らせ • Oct 25
Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022 Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022, at 10:00 AUS Eastern Standard Time. お知らせ • Oct 19
Pharmaxis Ltd Announces Positive Interim Data from Myelofibrosis Trial Pharmaxis Ltd. has concluded an interim analysis of data from 6 patients who have completed 6 months' treatment with PXS-5505 in its open label phase 2 clinical trial in patients with the bone marrow cancer myelofibrosis. The phase 2 trial known as MF-101 was cleared by the FDA under the Investigational New Drug (IND) scheme and aims to demonstrate that PXS-5505, the lead asset in Pharmaxis' drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs. These patients have very limited treatment options and a life expectancy of approximately 1 year. A total of 15 patients have been enrolled in the cohort expansion phase of the study with 6 patients having completed 24 weeks of treatment. Four patients have dropped out of the study due to a lack of clinical response. PXS-5505 has been well tolerated with no serious treatment related adverse events reported. 2/6 patients had clinically important improvement in symptoms. 5/6 patients had either stable or improved bone marrow fibrosis scores of 1 grade. 5/6 have stable or improved platelet and/or haemoglobin scores. No reductions were seen in spleen volume. A total of 18 clinical trial sites are now actively recruiting in Australia, South Korea, Taiwan and the US with two more sites due to open in Q4. Recruitment is expected to complete by the end of 2022 with top line results available in Third Quarter 2023. While Pharmaxis' primary focus is the development of PXS-5505 for myelofibrosis, the drug also has potential in several other cancers including liver and pancreatic cancer where it aims to break down the fibrotic tissue in tumours and enhance the chemotherapy treatment. An investigator led phase 1c study in newly diagnosed hepatocellular cancer patients, where PXS-5505 will be used in addition to immunotherapy standard of care, is due to commence recruitment at Rochester University New York in Fourth Quarter 2022. お知らせ • Sep 26
Pharmaxis Ltd Releases Promising Interim Data from Skin Scarring Study Clinical stage drug developer Pharmaxis announced interim data from the clinical trial of its topical anti scarring drug PXS6302 being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM, Director of the Western Australia Burns Service. The trial, known as SOLARIA2, is in 50 adult patients treated daily for scars of greater than one year in age and over 10cm2 in size for a period of 3 months. The first 8 patients treated were on active drug whereas the following 42 are being randomised 1:1 to active or placebo. Preliminary results from open label phase with 8 patients treated for up to 3 months on active drug are: Skin punch biopsies taken 24 hrs after application at the end of the treatment period, show skin penetration and high inhibition of the lysyl oxidase enzymes that, based on preclinical models, are fundamental to the scarring process. Reduction in the scarring biomarkers hydroxyproline and LOX was observed in the biopsies and based on preclinical models of the scarring process, suggests a normalisation of physiological processes and a disease modifying effect. Four patients withdrew from the study after experiencing redness and itching at the site of application that resolved on treatment cessation. In the second placebo controlled phase of the study, 24 out of the planned 42 patients have been recruited. In response to the adverse skin reaction seen with some patients in the unblinded active phase, the treatment regimen has been reduced from once daily to three times a week application to reduce drug exposure whilst maintaining a high level of enzyme inhibition. Final results are expected in H1 2023 when Pharmaxis hopes to confirm an acceptable safety profile, improvements in scar appearance and function for patients on active drug relative to those treated with placebo, and evidence that LOX inhibition is modifying scar tissue at a structural and biochemical level. In a separate development, UWA researchers last week published the preclinical studies performed in collaboration with Pharmaxis on topical treatment of skin scars with a pan LOX inhibitor that underpinned SOLARIA2. The preclinical studies, published in Nature Communications, clearly demonstrated that lysyl oxidase enzymes play a critical role in scar formation and maintenance by stabilising collagen, and driving scar stiffness and appearance. The inhibition of these enzymes by Pharmaxis' topically applied drug was shown to normalise collagen assembly and reduce fibrosis in different skin scar models (scleroderma, burn and hypertrophic scars). The preclinical data included in the publication were favourably reviewed by the FDA in preIND discussions with Pharmaxis where feedback was also useful in understanding potential endpoints of value in any regulatory process and the limitations of existing patient reported outcome measures. PXS6302 was discovered by the Pharmaxis research team at the company's Frenchs Forest laboratories. The project was supported by a National Health and Medical Research Council (NHMRC) development grant which funded extensive preclinical work executed in collaboration with UWA. The ongoing clinical trial in patients with established scars and the planned follow up study will both be conducted at the Fiona Stanley Hospital in Perth with financial support from Pharmaxis.